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novel anti-T3 Fabs (Henri Arola 2011). Here two different selection strategies were studied 
in order to optimize the amount of novel antibodies for T3 thyroid hormone. 
  
After selections, 768 individual recombinant antibody clones were produced in E.coli bac-
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Opinnäytetyö tehtiin valtion teknillisessa tutkimuskeskuksessa (VTT) bioanalytiikan tutki-
musryhmässä. Työn tarkoituksena oli uusien kilpirauhashormoni (3,3,5-trijodityroniini, T3) 
–spesifisten rekombinanttivasta-aineiden kehittäminen, tuottaminen ja tutkiminen. 
 
Vasta-aineita eristettiin in vitro aiemmin tehdystä ja validoidusta vasta-ainekirjastosta faa-
ginäyttötekniikan avulla. Työssä käytettyä vasta-ainekirjastoa on aiemmin käytetty onnis-
tuneesti T3-spesifisten vasta-aineiden eristykseen (Henri Arola 2011). Tässä työssä käy-
tettiin kahta eri valintamenetelmää parantamaan eristettävien T3-spesifisten vasta-
aineiden saantoa. 
 
Eristyksen jälkeen 768 yksittäistä rekombinanttivasta-ainekloonia tuotettiin E.coli baktee-
rissa. Vasta-ainekloonien T3-aktiivisuutta arvioitiin ELISA-testeillä, jotka toteutettiin robot-
tiaseman avulla. Tutkittavien kloonien määrää vähennettiin arvioimalla kloonien aktiivisuut-
ta ja spesifisyyttä T3:a kohtaan erilaisilla ELISA-testeillä. Jäljelle jääneiden kahdenkym-
menen kiinnostavimman kloonin kevyiden ja raskaiden ketjujen aminohappojärjestykset 
määritettiin. Lopulta kolme sitoutumisominaisuuksiltaan ja aminohappojärjestykseltään 
erilaista anti-T3-kloonia valittiin pienen mittakaavan tuottoon. Tuotetut vasta-aineet puhdis-
tettiin, jonka jälkeen niiden sitomisominaisuuksia määritettiin tarkemmin ELISA-testien 
avulla. 
 
Tuloksena saatiin yksi T3-spesifinen ja yksi korkea-affiniteettinen moni-spesifinen anti-T3 
klooni. Yhdessä aiemmin eristettyjen kloonien kanssa työ tuotti arvokasta tietoa T3 kilpi-
rauhashormonin tunnistamisesta vastaavista aminohapposekvensseistä.  
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1 Introduction 
 
Twenty-six years ago, the production of recombinant antibody fragments in bacteria 
was reported for the first time [1; 2]. Rapid development of modern molecular biology 
methods for modifying and expressing recombinant DNA has revolutionized the devel-
opment of the recombinant antibodies. The global market for research antibodies and 
pharmaceutical antibody drugs has reached the worth of 71 billion dollars [3; 4] and the 
share of recombinant antibodies is showing increasing trend in the market. 
 
Although the conventional immunoglobulin G (IgG) format still predominates in the 
therapeutics, smaller antibody fragments, such as antigen-binding fragment (Fab) and 
single-chain variable fragment (scFv) fusion-protein, are providing multiple advantages 
over the whole Ig molecules, especially, on application areas where small size, modifi-
ability, and faster and more economical production are preferred over the IgG [5]. 
 
The introduction and development of efficient antibody library display methods (e.g. 
phage display) and selection methods (e.g. biopanning) have enhanced dramatically 
the development of recombinant antibodies [6]. Respectively, in this study, phage dis-
play and biopanning are applied to the development of novel triiodothyronine (T3)-
binding antibodies from the previously constructed and validated recombinant antibody 
(Fab) library (Henri Arola, 2011). The library was constructed from a multi-immunized 
mouse, and it has already been successfully employed to the development of T3-
specific Fabs (Henri Arola, 2011). 
 
The target molecule of the study, T3, is widely considered to be one of the most active 
forms of biologically highly important thyroid hormones [7] and thus also an important 
analyte. The absence and weak availability of T3 binders with high affinity and specifici-
ty leaves a demand for better T3-specific antibodies (Tarja Nevanen, personal commu-
nication, 2014). 
 
Besides creating novel anti-T3 clones, the development and characterisation process is 
expected to yield valuable information concerning the structures responsible for the 
antigen binding abilities. This type of information will be useful for the understanding 
and modification of the antigen-binding domains of T3-specific antibodies.   
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The biopanning from a previously employed library will also provide information about 
the reproducibility and reliability of the methods and protocols that are applied to the 
antibody development process. 
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2 Theory 	  
2.1 The molecule of interest: T3 
 
T3 belongs to the family of thyroid hormones. These tyrosine-based signalling mole-
cules are the principal secretory products of the thyroid gland in vertebrates [8; 9]. Thy-
roid hormones are playing crucial role in the metabolism, growth, development, differ-
entiation, and physiological function of virtually all organ systems and tissues [10 – 12]. 
They consist of two benzene rings and are generally named after the number and the 
conformation of the iodine atoms bound to them. The quantity of the iodine atoms can 
vary from one to four. Thyroid hormones are accordingly named as mono- (T1), di- (T2), 
tri- (T3) and tetraiodothyronine (also known as thyroxine, T4). The number of the bound 
iodine atoms strongly affects to the biological functionality of the hormone. According to 
the current knowledge, the biologically most active forms of the thyroid hormones are 
T4’s more potent metabolites T3 and T2 [13]. Majority of the thyroid gland secreted thy-
roid hormones are in the form of T4, but it is estimated that more than 70 % of it will be 
deiodinated in peripheral tissues to T3 and part of T3 subsequently to T2 [7; 13]. T3-
specific antibodies were the main targets of this study, but to estimate their cross-
reactivity, they were also tested against T4. T3 and T4 are illustrated in Figure 1. 
 
 
Figure 1.  T3 and T4 molecules. In contrast to T4, T3 has only three iodine atoms.  
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Due to their broad range of biological functions, thyroid hormones have been exces-
sively studied for several decades. Based on its active role and high importance, T3 has 
a great demand for applications especially in fields such as diagnostics and therapeu-
tics. In diagnostics, reliable, sensitive and efficient detection methods are needed to 
determine hormone levels from samples. T3 tests are particularly important in diagnos-
ing and monitoring of hyperthyroidism, a condition in which the thyroid gland secretes 
excessive amounts of free thyroid hormones (T3 and T4). The opposite of hyperthyroid-
ism is called hypothyroidism, a condition caused by insufficient production and secre-
tion of thyroid hormones. The detection of free T3 is challenging due to its low levels in 
circulation. Free T3 levels of adults are typically ranging from 3 to 8 pmol / L [14]. Anti-
body fragments with high affinity and specificity against the T3, could be applied to cre-
ate more sensitive and specific tools for the detection of the T3 levels.  
2.2 Antibodies 
 
Antibodies, also called immunoglobulins, are immunologically active glycoproteins that 
are the most important part of humoral (antibody-mediated) immune system. They are 
produced and secreted by differentiated B-lymphocytes. The activation and differentia-
tion is triggered by the recognition of the antigen by the cell surface antigen receptor of 
the B-lymphocyte and usually requires helper T cells. 
 
Antibodies act in three main ways in the humoral immune system that protects the 
body from pathogens and other foreign particles. They can bind to the antigen and in-
hibit its toxic effects or pathogenicity (neutralization), invite phagocytic cells to destroy 
the recognized and antibody coated (opsonisation) pathogenic cells or particles, or 
activate the complement system that can strongly enhance the opsonisation or directly 
kill some pathogens. 
 
2.2.1 The general structure of an antibody 
 
Antibodies typically consist of two identical heavy and two identical light chains (Figure 
2). The polypeptide chains are connected via disulfide bonds by their cysteine resi-
dues. Each chain, both heavy and light, is constructed from series of approximately 
110 amino acids long sequences [12; 15]. These repeats form the discrete and com-
pactly folded domains of the antibody protein structure. The heavy and light chains are 
highly variable between antibodies, but the variability is focused mainly on the first pro-
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tein domains, also called the functional domains, of the amino-terminal ends of the 
chains, while the remaining domains are much more constant [16; 12]. The amino-
terminal variable domains of heavy (VH) and light chain (VL) form together the struc-
tures responsible for antigen binding abilities of the antibody, while the constant parts 
(CH and CL) correspond for the effector functions [16].  
 
Each variable domain (VH or VL) can be divided to smaller subregions. Conserved 
framework regions are responsible for the tertiary structure of the variable domains. 
Three hypervariable loops, also called complementary determining regions (CDRs), in 
each chain are located between the framework regions, and together these six loops of 
the heavy and light variable domains form the antigen-binding site of the antibody [15]. 
 
 
Figure 2. Schematic of IgG structure. Both the heavy and light chains consist of constant 
and variable domains (Heavy of CH1-3 and VH, light of CL and VL). Variable domains are 
responsible for the antigen binding abilities of the antibody. 
 
2.2.2 Recombinant antibodies 
 
Recombinant antibodies are antibodies produced by genetic engineering. Structures 
and properties of antibodies can be genetically engineered by recombinant DNA tech-
niques. Due to the domain structure of antibodies, it is particularly suitable to modify or, 
like in the most of the cases, to produce only the domains of the antibodies. Respec-
tively, majority of the recombinant antibodies, such as Fab and scFv, consist only of the 
functional fragments of antibodies [17].  
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A vast number of structural variations have been developed, but the most widely used 
format of recombinant antibodies is the Fab. Among with complete Ig molecules, Fabs 
have already gained regulatory approvals and they have been successfully applied as 
a treatment of cancer, infectious disease and inflammatory disease [5]. Fabs and other 
recombinant antibodies have been applied to create multivalent high-avidity reagents 
and fused with wide range of molecules and platforms [5]. Besides the Fab and scFv, 
the diverse group of recombinant antibodies include many other variations as well. The 
most common ones, Fab and scFv are illustrated in Figure 3. 
 
Figure 3. Basic structures of Fab and scFv molecules. Fab consists of a whole arm of an 
antibody, but scFv is a fusion protein including only the variable domains of a single an-
tigen-binding site. Despite their small size, both structures retain the antigen binding 
abilities of a whole IgG. 
 
2.3 Antibody gene libraries 
 
2.3.1 Antibody gene library 
 
Antibody gene library is a library constructed from a repertoire of antibody encoding 
genes. Complimentary DNA (cDNA) synthesized from murine or human B-
lymphocyte’s total RNA and the antibody genes are amplified by PCR (polymerase 
chain reaction) with special primers for heavy and light chains. 
 
The DNA of heavy and light chains are cut with specific restriction enzymes and ligated 
into a vector, which in phage display method is a phagemid plasmid. After the 
phagemid contains both of the chains, it can be used to express the antibodies in a 
host organism, such as E. coli. When displayed on phages, antibodies can be selected 
by their affinity against the desired antigen (see section 2.4). Different types of libraries 
can be constructed, but Fab and scFv libraries are the most common ones. Fab library 
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contains only the structures responsible for the antigen-binding abilities of an antibody, 
the first constant and variable regions from both, the light and the heavy chain (VH – 
CH1 and VL – CL1), whilst the scFv contains only the variable regions (VH and VL).  
 
Recombinant antibody library, such as Fab or scFv library, is typically constructed from 
immunized or naïve sources, however, they have also been successfully constructed 
completely synthetically [18] and combinatorially [19]. Immunized source, most com-
monly a mouse, is immunized with a desired immunogenic antigen to activate the pro-
duction of antigen-specific antibodies. Natural source, such as a mouse or a human 
that is not immunized, is called Naïve. Affinities of antibodies produced from immunized 
sources are corresponding to secondary immune response, whereas libraries of naïve 
sources produce antibodies against diverse group of antigens, but with weaker affini-
ties usually corresponding to the affinities of primary immune response [15].  
 
Unlike immunized and naïve sources, which are entirely based on naturally occurring 
sequence diversity, synthetic and combinatorial libraries are diversified by genetic en-
gineering, either according to design, randomisation or their combination [20]. In com-
binatorial approaches, naturally occurring sequences are combined to designed ones, 
but the fully synthetic libraries are completely based on computational in silico design 
and the composition of their antibodies is precisely defined and controlled [20].  
 
Although antibody repertoires with remarkably high diversity can be achieved with gene 
libraries, the diversity varies significantly between libraries. Typical library size for a 
phage-displayed library, constructed from an immunized source, is in the range of 108. 
Respectively, libraries provide a huge potential to the search of new recombinant anti-
bodies. The number and type of antibody clones obtained, are highly dependent on the 
size and diversity of the antibody library and it has been acknowledged that the quality 
of the library is one of the most important factors in all of the in vitro approaches of de-
veloping antibodies [20]. 
2.3.2 Developing of hapten-specific antibodies from an immunized source 
 
Haptens, such as thyroid hormones, are low molecular weight molecules, too small to 
induce a humoral immune response without assistance of a larger carrier. Due to their 
size, haptens are not recognizable to antigen receptors, unless presented as an 
epitope of larger structure. Therefore, haptens must be linked to macromolecules, such 
as immunogenic proteins or synthetic polymers [21], before immunizations [15]. Classi-
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cally, haptens are covalently bound to these carrier molecules via linkers; therefore, 
both the hapten and the carrier must have a reactive group for the attachment [22]. 
Linking of the haptens to other molecules can be significantly challenging and requires 
sophisticated chemistry [15].  
 
The linking itself may affect to the immunization and the properties of produced anti-
bodies [15]. Linking may, for example, cause the anti-hapten antibodies to recognise 
hapten and part of the linker with higher affinity than the native form of the hapten 
(‘bridge effect’), or distort the structure of the hapten and produce antibodies that rec-
ognise the conjugated form of the hapten with higher affinity and decrease the affinity 
for the hapten alone [15].  
 
In comparison with immunogenic target molecules, developing of hapten-specific anti-
bodies and their fragments can be significantly more challenging [15]. The methods 
and molecules applied to the conjugation of the hapten affect significantly to the anti-
bodies developed [23; 15]. It has been acknowledged that several factors, such as the 
carrier molecule, hapten-carrier ratio, linker molecule, the site of conjugation, and the 
number of carriers applied, affect the properties of the conjugate and therefore to the 
immunization and generated antibodies [23]. To raise the possibilities for success, it is 
highly advisable to carefully analyse and validate the hapten-protein conjugates; the 
degree of hapten conjugation should be estimated e.g. mass spectrometrically with 
matrix-assisted laser desorption/ionization (MALDI) (Tarja Nevanen, personal commu-
nication, 2014). 
2.3.3 In vitro display methods of recombinant antibody gene libraries 
 
Although various in vitro library display methods have been introduced and successful-
ly applied for the development of recombinant antibodies, the fundamental idea behind 
them is the same. Practically, all of the display techniques link the phenotype to its 
genotype (DNA or mRNA). Antibodies have been displayed, i.e. expressed, not only in 
vivo on microorganisms such as yeast, viruses and bacteria, but also in vitro by ribo-
some display and mRNA display [15]. The most popular display technologies are 
phage (bacteriophage) display and yeast display [6]. Also, the antibody (Fab) gene 
library of this study was displayed on the surface of a filamentous phage (M13), as a 
fusion with its coat protein (pIII). 
 
9 
 
2.4 In vitro selection of binders from phage-displayed libraries 
 
Antigen-specific antibodies (Fab, scFv etc.) can be selected from the phage-displayed 
antibody library in vitro according to their antigen binding properties with a method 
called “biopanning”. Biopanning involves library’s incubation with target antigen, remov-
ing of nonspecific phages (e.g. by washing), collection of specific binding phages, and 
enrichment of binders by propagation in host bacteria (e.g. E. coli) [24].  
 
Usually 3 – 4 rounds of panning are sufficient to enrich the binders [24]. Panning can 
be conducted with different techniques that differ in terms of selection method, washing 
protocol and elution methods. The antigen library can be panned in vitro against anti-
gens that are coated on a solid support (e.g. microplates, column matrices, sensor 
chips, polyester tubes or 96 well microtitre plates), in solution with biotinylated anti-
gens, on intact cell surfaces, on Western blots and on tissue sections [24]. Antibody 
clones expressing specificity against the antigen are collected or retained and the un-
specific clones removed. Method applied to remove the unbound clones can vary be-
tween different assay types, but usually unspecific clones are washed with suitable 
solution. 
 
After removing the unspecific clones, selected clones are collected by elution. Elution 
method has proven to be one of the most important factors affecting to the antibody 
outcome of the panning [15]. Due to its highly important role, multiple elution tech-
niques have been developed and applied to the panning of antibody libraries. Both high 
[25] and low pH [26] methods, different methods utilizing enzymatic cleavage such as 
trypsin [27] and DNAse [28], DTT method [29] and antigen competition [25] have been 
successfully applied as elution techniques. The efficiency of elution methods tends to 
vary case by case; thus the elution method should be carefully planned for each pan-
ning [28], and for the best possible results, multiple elution methods should be applied 
or at least tested [30]. 
 
In this study, the phage-displayed library was panned in vitro against T3-alkaline phos-
phatase (AP) conjugates. The conjugates were immobilized on the surface of streptav-
idin magnetic beads (Life Technologies). For clarification of the reaction conditions, 
main reaction components (hapten-protein conjugate (T3-AP), vector (filamentous bac-
teriophage M13), linker molecules and magnetic streptavidin beads are depictured be-
low (Figure 4 and Figure 5). 
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Figure 4. Simplified schematic presentation of magnetic streptavidin beads (Dynabeads® 
M-270 Streptavidin, diameter 2,8 µm) and M13 filamentous bacteriophages (880 nm in 
length and 6,6 nm in diameter [31]). 
 
 
Figure 5. Schematic presentation of molecules involved to the biopanning, enlargement 
from Figure 4. This simplified picture presents the binding of a hapten-specific Fab 
clone to an immobilized hapten-protein conjugate. The purpose of the picture is to clari-
fy particle sizes and the panning process. In reality, the surface of the magnetic strep-
tavidin bead would be coated almost completely with the biotinylated hapten-protein 
conjugates (T3-AP + biotin linker). Dimensions of the structures are in realistic scale to 
each other (M13 [31], Fab [32], T3 calculated with MarvinSpace 15.3.30.0, AP [33], bio-
tin linker and magnetic streptavidin beads (manufacturers specifications, EZ-Link Sulfo-
NHS-SS-Biotin and Dynabeads® M-270 Streptavidin). 
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2.5 Applications of phage-displayed recombinant antibodies 
 
Since its development in 1985, phage display has become the most successful in vitro 
antibody selection method [34]. It has proven to be a powerful tool in the development 
of recombinant antibodies, and has already proven its value in fields of research, diag-
nostics and therapeutics [34]. All in vitro methods have two major advantages: they can 
be applied to an enormous range of antigens and the broad flexibility in the selection 
conditions that can be adapted to adjust the selection pressure [20]. Some of phage 
display’s advantages over the other in vitro methods are robustness, which gives it a 
great potential for automation, and the high stability of phage, which enables applying 
extreme conditions to the selection procedure [20; 34]. 
 
Antibody phage display can be applied to produce a range of recombinant antibody 
formats limited only by E. coli’s folding machinery and the periplasmic expression effi-
cacy [20; 34]. However, due to the phage displays ability to link the phenotype to the 
genotype, this limitation can be overcome by reconverting the recombinant antibody 
fragment to the antibody format of interest (e.g. Fab or scFv) and producing it in differ-
ent production host capable to correct glycosylation and expression (e.g. modified 
yeast or human cell) [34; 6]. 
 
The diversity of recombinant antibody applications is enormous. Different fields of ap-
plications and the desired application define the specific requirements for the particular 
antibody; for example, in therapeutics special attention must be given to the safety, 
manufacturability, and formulation of the antibody product [20]. Immunogenicity and 
safety are particularly problems with nonhuman antibodies and their fragments. In such 
cases, antibodies are usually modified either by chimerisation or humanisation [34]. In 
chimeric antibody the constant regions are human and the variable regions murine, 
whereas in humanisation human counterparts replace also the murine framework re-
gions of the variable domains [34].  
 
Although Ig molecules still predominate in the therapeutics, there are many recombi-
nant antibodies in preclinical and clinical development [5]. Besides the growing interest 
in their development, for example Fabs have already gained clinical approvals from 
FDA, e.g. as an antidote for rattlesnake bite (CroFab®, BTG International Inc.), and as 
a treatment of digoxin overdose (DigiFab®, BTG International Inc.), cardiovascular dis-
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ease (ReoPro®, Janssen Biologics B.V.), rheumatoid arthritis (Cimzia®, UCB, Inc.), 
and age related macular degeneration (Lucentis®, Genentech USA, Inc.). 
 
Due to modifiable structure and size, faster and more economical production, and re-
tained targeting specificity of whole Ig molecules, recombinant antibodies provide pow-
erful tools also for research and diagnostic applications [5]. Especially promising appli-
cation areas are biosensors [5; 35], in vivo medical imaging [5], in vitro immunoassays 
[5; 35], in vivo tumor and clot-imaging [5], and tuning and detecting the activity of cell 
proteins in vivo [35]. Antibodies are already standard tools for many methods of basic 
research such as immunoblot, ELISA, immunofluorescence microscopy, flow cytome-
try, purification of molecules or cells by affinity chromatography, and microarrays [34]. 
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3 Materials and methods 
 
The main steps of the thesis are presented in the flow diagram (Figure 6) below. 
 
 
Figure 6. Flow diagram of the main steps of the thesis. 
 
3.1 The selection and screening of the T3-specific clones  
 
3.1.1 The phage library transformation 
 
An antibody library used for screening and selection was built by combining four differ-
ently cloned pools of the Addams library, a multi-immunized library previously con-
structed and validated by Henri Arola (2011). Transformation of the library was imple-
mented via electrotransformation. Cells applied for the transformation were from a 
commercial electrocompetent E. coli strain, XL1-Blue (Agilent). 
 
For the transformation, one µg of DNA was used per 100 µL of the XL1-Blue cells. The 
DNA-libraries were mixed with the cells and the tubes were kept on ice for a minute. 
The cells were transferred to precooled Ø 0,2 cm electrocuvettes (Cuvettes Plus™, 
Model No. 620, BTX), in which the electroporation was carried out with an initial voltage 
of 2,5 kV. After the electric shock, the cells were immediately gathered and washed 
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three times with 1 mL of Super Optimal broth with Catabolite repression (SOC) and 
transferred within the solution to 8 mL test tubes. The cells were incubated at 250 rpm 
shaking at a temperature of 37 °C for an hour. 
 
After the incubation, 7 mL of Super broth (SB) containing 20 µg / mL of carbenicillin 
(CARB, Sigma-Aldrich Co.) and 10 µg / mL tetracycline (TET, Sigma-Aldrich Co.) was 
added to the tubes. The antibiotics were added to prevent the growth of untransfor-
mated cells. After the addition, 100 µL of the cells were cultivated on Luria broth (LB) 
plates with 100 µg of TET per 1 mL of LB. The plate count was applied to determine 
the transformation efficiency and the library size. 
 
The tube cultivation of the cells was continued under the previously described condi-
tions for an hour before the addition of CARB to the final concentration of 50 µg / mL. 
The antibiotic addition was followed by a one-hour incubation in the conditions analo-
gous to the previous one. The incubated cells were infected with 1 mL of VCSM13 
helper phages (Stratagene, ~1012 phage particles / mL) and the tubes were held for 30 
minutes at a temperature of 37 °C without shaking to enhance the infection.  
 
After the infection, the cultures were transferred to 90 mL of preheated (37 °C) SB con-
taining the same concentrations of antibiotics as the cultivation media. The cultures 
were incubated in the volume of 100 mL for two hours under the incubation conditions 
mentioned above. After the incubation, the cultures were treated with 70 µg / mL kan-
amycin (KANA, Sigma-Aldrich Co.) and cultivated overnight at a temperature of 37 °C 
and 250 rpm shaking. KANA was added to the cultivation media by means of allowing 
the surviving and proliferating only for the VCSM13 infected cells. 
 
The cultures were centrifuged for 15 minutes with 4 000 rpm to separate the cells from 
the cultivation media. The supernatant containing the cell-secreted phages was sepa-
rated from the cultivated cells by pouring and mixing it to 25 mL of precooled precipita-
tion solution, which was containing 2,5 M NaCl and 20% of polyethylene glycol (PEG 
6000, Sigma-Aldrich Co.). In order to efficiently precipitate the phages, the mixture was 
kept on ice for 30 minutes. The precipitated phages were centrifuged to the bottom of 
the tube with 9 000 rpm at 4 °C for 20 min. The supernatant was disposed from the 
centrifugation tube and the pellet was resuspended to 2 mL of phosphate-buffered sa-
line (PBS). The 2 mL of phages was then divided to two 1,5 mL Eppendorf tubes. The 
tubes were centrifuged with 14 000 rpm for 5 minutes and reprecipitated as before with 
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250 µL of the precipitation solution. The phages were centrifuged for 8 min with 11 000 
rpm and the supernatant was carefully removed. The compounded pellet was resus-
pended to 1 mL of PBS and stored at a temperature of 4 °C. 
3.1.2 The biotinylation of the hapten-protein conjugates 
 
Hapten-protein conjugates were constructed by combining protein carriers, AP mole-
cules (Sigma-Aldrich Co.), to haptens, T3 molecules (Sigma-Aldrich Co.). The mass 
spectrometrically (matrix-assisted laser desorption/ionization, MALDI) validated hapten-
protein conjugates were provided by Antti Tullila. The conjugates and free AP mole-
cules were biotinylated for the selection phase. 
 
0,2 mg of the T3-AP-conjugates and AP molecules were diluted to 200 µL of double de-
ionized water. A Twenty-fold molar excess of Sulfo-NHS-SS-biotin (EZ-Link™, Thermo 
Fisher Scientific Inc.) was added and mixed to the dilutions. The additions and mixings 
were conducted in three steps. After the last additions, the tubes were held for two 
hours in shaking at a room temperature (RT). 
 
The solutions were transferred from Eppendorf tubes to Millipore’s 10 000 MWCO cen-
trifugal filter tubes (Amicon® Ultra - 0,5 mL 10 K Centrifugal Filters) and washed 5 
times with 500 µL of PBS before resuspending to 160 µL of PBS. 
 
The quantity of the proteins obtained was determined by Thermo Scientific’s Pierce™ 
BCA Protein Assay kit with human serum albumin (HSA) standards (4, 2, 1, 0,5 and 
0,25 mg / mL) provided by Hannakaisa Jaatinen. The assay was conducted according 
to the manufacturer’s instructions. The detection was exploited after 30 minutes at a 
wavelength of 560 nm with SPECTROstar Omega spectrometer (BMG LABTECH 
GMBH). 
 
The degree of the biotinylation was measured with an ELISA test. A streptavidin coated 
96-well plate (KaiSA96-C96 Clear, Kaivogen Oy) and an AP control were applied for 
the assay. 0,5 µg of the analyte and the AP were diluted to 100 µL of PBS and incu-
bated on the plate for 20 min with shaking at a RT. 100 µL of Para-
Nitrophenylphosphate (pNPP, Sigma-Aldrich Co.) diethanolamine (DEA, Reagena) 
solution (2 mg / mL) was implemented for the detection. Absorbance values were 
measured at a wavelength of 405 with SPECTROstar Omega spectrometer after 20 
and 30 minutes of incubation. 
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Step	  # Function Mixing	  included	  (Yes	  /	  No) Reagents 	  Volume Duration
1 Collection	  of	  beads Yes 100	  µl	  /	  ml	  of	  SA-­‐Beads 250	  µl 30	  sec
2 Coating	  of	  SA-­‐beads Yes 50	  µg	  /	  ml	  biotinylated	  protein	  molecules 250	  µl 1	  h
3 Washing Yes PBST	  (0,05	  %	  of	  Tween20) 500	  µl 20	  sec
4 Washing Yes PBST	  (0,05	  %	  of	  Tween20) 500	  µl 20	  sec
5 Blocking Yes Biotin	  +	  PBST	  (0,05	  %	  of	  Tween20) 500	  µl 15	  min
6 Washing Yes PBST	  (0,05	  %	  of	  Tween20) 500	  µl 20	  sec
7 Washing Yes PBST	  (0,05	  %	  of	  Tween20) 500	  µl 20	  sec
8 Ejecting	  of	  processed	  beads Yes PBST	  (0,05	  %	  of	  Tween20) 100	  µl 1	  min
KingFisher™:	  Coating	  and	  Blocking	  of	  Streptavidin	  (SA)	  Beads
3.1.3 The hapten-protein conjugate coating of the magnetic beads 
 
Magnetic streptavidin beads (Dynabeads® M-270 Streptavidin, Invitrogen™, Life 
Technologies), which were to be used in the selection phase, were coated with the 
biotinylated hapten-protein conjugates (section 3.1.2) to enable the capturing of hap-
ten-specific Fab clones. The control beads were coated with biotinylated AP molecules 
(section 3.1.2). The goal was to saturate the surfaces of the beads with the biotinylated 
molecules. After the coating, all of the possibly uncoated surfaces were blocked with 
the biotin. KingFisher™ Duo was applied to efficiently combine and perform the proto-
cols for both the coating and blocking. 
 
KingFisher™ Duo’s program created for the selection phase included 8 steps and took 
approximately 1 h and 20 min. The whole process was designed to be implemented on 
a deep 96-well plate (MASTERBLOCK®, 2 ml V-Shaped, Greiner Bio-one), compatible 
with KingFisher™ Duo. The plate was prefilled with desired reagents, and the premedi-
tated order of the reagents enabled the right reactions when magnetic beads were 
shifted from a well to another. The main working steps of KingFisher™ Duo’s program 
are described below in table Table 1. 
 
Table 1. Summarization of the KingFisher™’s program designed for the coating and 
blocking of magnetic streptavidin beads. 
 
After completing the protocol, successful coating of the beads was ensured by applying 
an ELISA-test. Uncoated SA-beads were utilized as controls. pNPP DEA solution (2 
mg / mL) was applied to detect the amount of AP in the sample and control solutions. 
Absorbance values were measured at a wavelength of 405 with SPECTROstar Omega 
spectrometer. 
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3.1.4 The selection of specific anti-T3 clones through biopanning 
 
The selection, also called as biopanning, was applied to enrich the bacteriophage M13 
clones that expressed the T3-specific antibodies. As a starting material for the first se-
lection round, was the bacteriophage pool from the phage library transformation (sec-
tion 3.1.1). The clones obtained as a result of each selection round were applied as a 
starting material for the following round. Thereby, the selection enriched only the se-
lected clones of each round. The needed amount of the clones for each of the selection 
rounds was obtained by utilizing E.coli (XL1-Blue) cells to produce the selected phag-
es. The selection was conducted to the clones by utilizing two different elution methods 
in parallel. The elution methods applied were the alkaline and acidic elution. 
 
The KingFisher™ Duo was applied for the selection step. The biopanning was con-
ducted with the previously created hapten-protein coated magnetic streptavidin beads 
(Section 3.1.3) and it was consisted of five selection rounds. In order to increase the 
selection pressure between the rounds, reaction conditions of the selection were grad-
ually hardened for each of the rounds. 
 
Unlike the reaction conditions, the basic structure of the protocol was remained mainly 
the same during all of the rounds. Each selection round was began with depletion and 
binding, either simultaneous or as separated steps. The amounts of the phages and 
hapten-protein coated magnetic streptavidin beads used to the binding were utilized to 
affect the selection pressure. After the binding phase, three washing cycles followed. 
The washings were gradually elongated towards the fifth round. The final step of King-
Fisher™’s protocol was the 30 min elution of the selected phages from the hapten-
protein coated beads. After the elution, the detached phages in 100 µL of the elution 
mixture, either glycine-HCl (0,1 M pH 2,2) or tetraethylammonium hydroxide (TEA, ~ 
2,7 M, pH 11,7, Sigma-Aldrich Co.), were manually neutralized either with 8,5 µL of 1 M 
Tris pH 9,5 or with 135 µL of 1 M Tris pH 7,4 depending on the elution method used. 
The specific conditions and the differences between each round are described in detail 
below in Table 2. 
  
18 
 
Table 2. Detailed protocols for each of the selection rounds of the biopanning. The en-
riched clones were produced in XL1-Blue cells between each round. 
 
 
For the production of the selected phages, XL1-Blue cells were cultivated at 30 mL of 
SB containing 10 µg / mL TET. The cells were cultivated 2,5 hours until the cell cul-
ture’s absorbance, measured at wavelength of 600 nm (OD600), had reached the val-
ue of 1. 3 mL of the XL1-Blue cells were infected with the neutralized bacteriophages 
for 30 min at 37 °C. Also, 1 mL of the cells were infected with the same protocol, but 
instead of the elution mixture with 1:10 000 dilution of the original input phage pool of 
the current round. 
 
After the infection 7 mL of SB with 10 µg / mL TET and 20 µg / mL of CARB was mixed 
to 3 mL of the cultivation. 100, 10 and 1 µL of the cells from the 10 mL cell culture and 
10, 1, 0,1 and 0,01 µL from the 1 mL culture were cultivated on LB plates with 100 µg 
of TET per mL of LB. With the plate cultivation it was possible to estimate the effect of 
the selection on the ratio between input and output of each round. 
 
Round
type AP-­‐SS-­‐Biot-­‐SA-­‐beads beads	  (T3-­‐AP-­‐SA) 5	  µl cycles 3
reagents
10	  µl	  AP-­‐SS-­‐Biot-­‐SA-­‐beads	  	  	  	  	  	  	  	  
300	  µl	  PBST	  (0,05	  %	  Tween20)	  	  	  	  	  	  	  	  	  
200	  µl	  phage	  pool
depleted	  phage	  pools	  (µl) 200	  µl
duration	  
per	  cycle	  	  	  	  	  	  	  
20	  sec
duration 2	  h duration o/n duration 30	  min
type AP-­‐SS-­‐Biot-­‐SA-­‐beads beads	  (T3-­‐AP-­‐SA) 5	  µl cycles 3
reagents
10	  µl	  AP-­‐SS-­‐Biot-­‐SA-­‐beads	  	  	  	  	  	  	  	  
300	  µl	  PBST	  (0,05	  %	  Tween20)	  	  	  	  	  	  	  	  	  
200	  µl	  phage	  pool
depleted	  phage	  pools 200	  µl
duration	  
per	  cycle	  	  	  	  	  	  	  
20	  sec
duration 2	  h duration o/n duration 30	  min
Round
type cycles 3
reagents
duration	  
per	  cycle	  	  	  	  	  	  	  
1	  min
duration duration 30	  min
type cycles 3
reagents
duration	  
per	  cycle	  	  	  	  	  	  	  
1	  min
duration duration 30	  min
type cycles 3
reagents
duration	  
per	  cycle	  	  	  	  	  	  	  
5	  min
duration duration 30	  min
V
reagents
Acidic:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Glycine-­‐HCl	  (pH	  2.2)	  
Alkaline:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
TEA	  (pH	  ~11,75)
III
reagents
Acidic:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Glycine-­‐HCl	  (pH	  2.2)	  
Alkaline:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
TEA	  (pH	  ~11,75)
IV
reagents
Acidic:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Glycine-­‐HCl	  (pH	  2.2)	  
Alkaline:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
TEA	  (pH	  ~11,75)
soluble	  combined	  with	  binding
20	  µg	  soluble	  AP	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4µl	  T3-­‐AP-­‐SA-­‐beads	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
200	  µl	  bacteriophages	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
300	  µl	  PBST	  (0,05	  %	  Tween20)
2	  h
soluble	  combined	  with	  binding
20	  µg	  soluble	  AP	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3	  µl	  T3-­‐AP-­‐SA-­‐beads	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
200	  µl	  bacteriophages	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
300	  µl	  PBST	  (0,05	  %	  Tween20)
ElutionsCombined	  depletion	  and	  binding
Selection:	  Rounds	  I	  -­‐	  V,	  T3
Depletion Binding
I
ElutionsWashes
reagents
Acidic:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Glycine-­‐HCl	  (pH	  2.2)	  
Alkaline:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
TEA	  (pH	  ~11,75)
II
reagents
Acidic:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Glycine-­‐HCl	  (pH	  2.2)	  
Alkaline:	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
TEA	  (pH	  ~11,75)
2	  h
soluble	  combined	  with	  binding
20	  µg	  soluble	  AP	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2	  µl	  T3-­‐AP-­‐SA-­‐beads	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After increasing the CARB’s concentration to 50 µg / mL, the 10 mL cultivations were 
incubated one hour at 37 °C with 225 rpm shaking. The incubation was followed by an 
infection with helper phage VCSM13. The infection and cultivation after it were per-
formed similarly to the protocol of the phage library transformation, which is described 
in section 3.1.1. 
 
After the overnight production of the selected bacteriophages, they were precipitated 
with the same protocol as during the phage library transformation (section 3.1.1). The 
precipitated phage pools were applied as a starting material for the next round of the 
selection. After five selection rounds the pools were tested with a phage ELISA (section 
3.1.5). 
 
3.1.5 The phage ELISA 
 
Two MaxiSorp® NUNC-IMMUNO C96 (Thermo Scientific Ltd.) 96-well plates were 
coated overnight with 3 µg / mL T3-HSA and HSA Na-bicarbonate (0,1 M pH 9,6) solu-
tions, 100 µl per well. 
 
The precipitated phage pools, both the alkaline and acidic eluted (section 3.1.4), were 
diluted to three dilutions (1:10, 1:100, 1:1000) and the 96-well plates were washed 
three times with 0,05 % PBST and blocked for one hour in shaking at RT with 280 µl of 
SuperBlock® (Thermo Scientific Ltd.) 0,05 % Tween® 20 (Sigma-Aldrich Co.) solution 
per well. Plates were washed as before and 100 µl of phage dilutions were incubated 
on the plates for an hour in conditions described above. After incubation, plates were 
washed as described before and 100 µl of HRP-conjugated anti- M13 detection anti-
body (Sigma-Aldrich Co.) was added per well. Plates were incubated and washed 
analogously to earlier steps, and 100 µl of ABTS substrate (1 mg ABTS and 7 µl of 
double de-ionized water (DDIW) in 4,4 mL of 50 mM citrate buffer) was added per well. 
Intensities of the occurred colour reactions were measured at a wavelength of 405 nm 
with SPECTROstar Omega spectrometer. 
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3.1.6 The primary screening (ELISA) 
 
Primary screening was conducted only to the phage pools indicating specificity against 
T3 in the phage ELISA (section 3.1.5). Respectively, the rounds from two to five from 
both, the acidic and the alkaline elutions, were represented and the first rounds were 
excluded. SAMI, an automated robotic working station (specifications classified), was 
employed for the ELISA screenings, which were exploited to estimate the T3-specificity 
and affinity of the clones. 
 
As a starting material were the output plate cultivations from the T3-specific pools 
(rounds II – V). 96 XL1-Blue clones from each of the plate cultivations were collected 
and transferred to 96-well plates (Pharmacia Ab) filled with 100 µL of SB containing 
100 µg / mL ampicillin (AMP), 10 µg / mL TET and 1 % of glucose. The cells were in-
cubated overnight at 37 °C, with 620 rpm shaking and at a relative humidity level of 80 
%. For the overnight cultivations, the plates were sealed with gas exchange allowing 
membranes (4titude®, Gas Permeable Seal) and incubated in plastic bags to prevent 
unwanted evaporation of the media. 
 
On the second day, 10 µL of the cultivated cells were transferred to deep incubation 
plates (MASTERBLOCK®, V-shape 2 mL, Greiner Bio-one) containing 500 µL of SB 
supplemented with 10 µg / mL TET and 100 µg / mL AMP. 20 µL of 85 % glycerol was 
added to the remaining 90 µL of the cultivations. The cultures were stored at -20 °C. 
The Induction plates were incubated 2,5 hours at 37 °C with 620 rpm shaking at 80 % 
of relative humidity. After the incubation 10 µL of induction media, 10 mM isopropyl-
beta-D-thiogalactopyranoside (IPTG, Sigma-Aldrich Inc.) SB containing 100 µg / mL 
AMP, was added to the cultivations by the robot. The induction plates were sealed with 
the gas exchange allowing membranes (4titude®, Gas Permeable Seal) and incubated 
overnight in plastic bags at 37 °C with 620 rpm shaking at 80 % of relative humidity.  
 
On the same day, a total of 24 96-well plates (NUNC-IMMUNO PLATE C96) were 
coated, eight plates with each of the conjugates (1 µg / mL of T3-HSA, T4-HSA or HSA 
in 0,1 M sodium bicarbonate buffer, pH 9,6). The conjugates were provided by Antti 
Tullila and the coating was implemented overnight at 4 °C. 
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On the third day, before proceeding to SAMI, the cells were separated from the secret-
ed Fabs (supernatant) by centrifuging the plates with 4 000 rpm for 10 min. SAMI’s 
ELISA protocol for 24 96-well plates was previously programmed by Henri Arola. Oth-
erwise the protocol was identical to the phage ELISA’s (section 3.1.5), but 0,5 % bo-
vine serum albumin (BSA, Sigma-Aldrich Co.) in PBS was applied for the 30 min block-
ing step and Anti-kappa AP 1:1000 (SouthernBiotech) in 0,5 % BSA PBS was em-
ployed as the detection antibody and incubated on the plates for 30 min. Detection so-
lution, 2 mg pNPP per 1 mL of DEA, revealed the amount of the attached detection 
antibody in each well. Intensity of the occurred colour reaction was measured after 30 
min at a wavelength of 405 nm. Execution of the whole 24 plate ELISA protocol took 
approximately 7,5 hours. Henri Arola’s Anti-T3 Fab (Anti-T3 DTT T3.K4.C5) was em-
ployed as a control. 
 
According to results of the primary ELISA, twenty of the most promising or interesting 
clones were selected for sequencing and further characterization. The decisions were 
made by comparing the Fabs’ specificities against the T3-HSA, T4-HSA and HSA. 
 
3.2 The characterization of the screened anti-T3 clones 
 
3.2.1 The sequencing of plasmidial DNA 
 
The selected anti-T3 XL1-Blue clones were picked from the -80 °C storage and cultured 
in 4 mL of SB with 100 µg/ mL AMP, 10 µ / mL TET and 1 % glucose overnight at 37 
°C. Plasmidial DNA of phagemid (9.2, VTT) vectors was isolated from the cultivated 
cells by applying Plasmid & DNA Purification kit (NucleoSpin® Plasmid, MACHEREY – 
NAGEL). The isolated DNA was sequenced with specific primers (GATC-1867 and 
GATC-6044, GATC Biotech AG). Data obtained from the sequencing was analysed 
with Geneious 6.1.8. 
 
3.2.2 The competitive ELISA 
 
In order to produce the Fabs, the twenty selected anti-T3 clones were cultivated in 4 mL 
of SB with 100 µg / mL AMP and 10 µg / mL TET for 2,5 h at 37 °C with 220 rpm shak-
ing. Induction of the cultivated cells was implemented by adding protein expression 
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inducer (IPTG) to the final molar concentration of 1 mM. The cell cultures were incu-
bated overnight at 30 °C with 220 rpm shaking. 
 
During the anti-T3 cell cultivation MaxiSorp® NUNC-IMMUNO C96 plates were coated 
with T3-HSA (100 ng T3-HSA (Antti Tullila) / 100 µl sodium bicarbonate, pH 9,6) and 
incubated overnight at + 4 °C. 
 
After the overnight incubation, the cultivations were centrifuged for 7 minutes with 
6 000 g and supernatant was collected to 2 mL tubes. Right amounts of the T3 and T4 
molecules, which were provided by Antti Tullila, were diluted to PBS containing 1 % of 
dimethyl sulfoxide (DMSO, Sigma-Aldrich Co.) to obtain the final molar concentration of 
20 µM of each hapten. 125 µL of each supernatant, containing the produced fab, was 
mixed and preincubated with 125 µL of each hapten dilution for 1 h. 
 
During the preincubation, the coated 96-plates were first washed three times with 300 
µL of PBS and then blocked with 285 µL of PBS with 0,5 % BSA. The blocking was 
applied for 30 min at RT with 220 rpm shaking and followed by washings identical to 
the previous ones. 
 
After the preincubation, the competed supernatants were transferred to the coated and 
blocked ELISA plates, 100 µL of each to two wells. The ELISA plates were incubated 
for 1 h at RT with 220 rpm.  
 
After the incubation the plates were washed as described before. Secondary antibody, 
1:2000 dilution of Anti-kappa AP (SouthernBiotech) in 0,5 % BSA PBS, was added to 
the plate (100 µl per well). The plates were incubated for 1 h at the same conditions as 
before and washed as described above. The amount of AP was detected by adding 
100 µL of the detection dilution, 2 mg pNPP per 1 mL of DEA solution, to each well. 
Intensities of occurred colour reactions were measured at a wavelength of 405 nm with 
SPECTROstar Omega spectrometer. 
 
According to the results of the competitive ELISA and the sequencing data, six of the 
most promising clones were selected for T3 and T4 cross reactivity testing with a sec-
ondary ELISA. 
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3.2.3 The cross reactivity testing of the T3-specific clones 
 
The protocol of this ELISA is described in the previous section. The only change to the 
previous protocol was that the blocking solution (0,5 % BSA in PBS) was replaced with 
SuperBlock® + 0,05 % Tween® 20. Competiveness of the 6 previously selected clones 
was measured with T4 and T3 in three different concentrations, 20, 2 and 0,2 µM. 
 
As a result, the ELISA gave valuable information about the specificity of Fabs’ against 
the T3 and T4. On the basis of the obtained data, three of the six tested Fab clones 
were chosen for a small-scale production (2 L) and further characterization. 
 
Plasmidial DNA, the phagemid (9.2, VTT) vectors, of the selected clones was isolated 
by applying MACHEREY – NAGEL’s Plasmid & DNA Purification kit (NucleoSpin® 
Plasmid). 
3.3 The production of the T3-specific Fabs 
 
3.3.1 The transfer of the Fab coding sequence from phagemid to pKKTac 
 
In order to enable the later purification of the produced Fabs, Fab coding sequences 
were transferred from the phagemids (9.2, VTT) to histidine tagged pKKTac vectors. 
 
The isolated plasmidial DNA of the clones selected to the larger scale Fab production, 
was digested for 4,5 hours at 37 °C and stored at 4 °C. Digestion mixture contained 2 
µL of both endonucleases NheI (New England Biolabs) and NotI (New England Bi-
olabs), 5 µL CA (cuts all) buffer (pH 7,5) with β-mercaptoethanol (Fluka BioChemika), 
0,5 µL BSA (20 mg / mL) and 15,5 µL DDIW. 
 
The Fab coding regions of the phagemid plasmids were separated by agarose gel elec-
trophoresis. The electrophoresis was carried out with MSCHOICE (Cleaves Scientific 
Ltd.) and GeneRuler™ 1 kb DNA Ladder (Thermo Scientific). 7 µL of DNA Safe colour 
was added per 100 mL of the 1 % agarose gel.  
 
The samples, digested plasmidial DNA, and the control, 4 µL of undigested plasmidial 
DNA, were prepared by adding 1/6 volume of 6x DNA Loading Dye (Thermo Scientific) 
to them. The samples were kept in a +65 °C heat block for 10 minutes and cooled back 
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to RT before loading them into pre-cast wells in the agarose gel. Applying of an electric 
field separated the DNA fragments. The electrophoresis was run with the voltage of 80 
V. 
 
UV-light table of Molecular Imager Gel Doc™ XR+ (Bio-Rad Laboratories Inc.) was 
exploited for visualization and cutting off of the separated DNA bands from the agarose 
gel. The severed inserts were purified with MACHEREY – NAGEL’s NucleoSpin® Gel 
and PCR Clean-up kit. 
 
In order to determine the approximate DNA concentration of the purified inserts, 
NanoDrop 1000 spectrophotometer (Thermo Scientific) was applied. Absorbance was 
measured from a sample volume of 2 µL by using NanoDrop’s preset configurations for 
nucleic acid measurements. 
 
The mixtures with total volume of 10 µL contained 50 ng of the insert DNA, 100 ng of 
twice NheI and NotI digested pKKTac vector, 1 µL of 10x buffer, 1 µL T4 ligase, 1 µL 
rATP (ribose adenine triphosphate, Thermo Fisher Scientific Inc.) and for the rest of the 
volume DDIW. The ligation mixtures were incubated 2 h at RT. The efficiencies of the 
ligations were estimated by selective plate cultivations after the transformation of the 
ligated pKKTac plasmids to the XL1-Blue competent cells (section 3.3.2). 
 
3.3.2 The heat shock transformation of the pKKTac plasmid vectors 
 
The ligated pKKTac plasmid vectors were transformed to XL1-Blue competent cells 
(VTT) via heat shock transformation. 200 µL of the heat shock competent XL1-Blue 
cells were added to 5 µL of each of the ligation mixtures and incubated on ice for 30 
min. The tubes were then transferred for two minutes to a 37 °C heat block and then 
stabilized on the ice for two minutes. 400 µL of SOC was added to each of the tubes 
and the cells were cultivated for one hour at 37 °C with 220 rpm shaking. The cells 
were diluted in SB to 1:10 and 1:100. 100 µL of the dilutions were cultivated on LB 
plates supplemented with 100 µg of AMP per mL of LB and incubated at 37 °C over-
night. The colonies were counted to enhance the ratio of the transformation. 
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3.3.3 The cultivation and selection of the pKKTac containing clones 
 
Four colonies from each of the plate cultivated pKKTac containing XL1-Blue clones 
(section 3.3.2) were isolated and cultivated separately in 4 mL of SB with 10 µg / mL 
TET, 100 µg / mL AMP and 1 % glucose. The cells were incubated overnight at 37 °C 
with 220 rpm shaking. The plasmidial DNA of 2,5 mL of the cells was purified by apply-
ing MACHEREY – NAGEL’s Plasmid & DNA Purification kit (NucleoSpin® Plasmid). 
 
100 µL of the cells were transferred to 3900 µL of SB supplemented with 10 µg / mL 
TET, 100 µg / mL AMP and 0,01 % glucose. The cells were incubated at 37 °C with 
220 rpm shaking until the cultivation media reached the absorbance of one. The ab-
sorbance was determined with the OD600 method. In order to produce the Fabs, 4 µL of 
1M IPTG and AMP (final concentration of 100 µg / mL) was added to the media. The 
clones were incubated overnight at 37 °C with 220 rpm shaking. 
 
On the next day, the cells were centrifuged from the supernatant (1 min with 13 000 
rpm). The supernatants were retained and a primary ELISA with protocol identical to 
section 3.1.5, differing only by the coating solution, 1 µg / mL T3-HSA and HSA Na-
bicarbonate (0,1 M pH 9,6) in this assay, and the detection antibody, Anti-kappa AP 
1:2000 (SouthernBiotech) in SuperBlock® supplemented with 0,05 % Tween® 20 in 
this assay, and by the detection substrate, 2 mg pNPP per 1 mL of DEA solution in this 
assay, was applied to the twelve undiluted supernatants. 
 
Every set of four clones, collected from the same plates, consisted of theoretically iden-
tical clones, but the ELISA-test was performed to ensure it. An immunoblot (protocol 
described in section 3.4.2) was also conducted to enhance the uniform and sufficient 
production rates of the Fabs. The most specific and sufficiently producing individual 
was selected from each of the three clones. 
 
3.3.4 The transformation of the pKKTac plasmids to production strain 
 
The selected and purified pKKTac plasmids (section 3.3.3) were transformed to a pro-
duction strain of E. Coli (RV308) by heat shock transformation (protocol described in 
the section 3.3.2). After the transformation the RV308 clones were plate cultivated 
overnight on LB AMP (100 µg/ mL) plates at 37 °C. Colonies were counted to enhance 
the ratio of the transformation. 
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3.3.5 The small-scale fermentations for the three selected clones  
 
Small-scale (2 L) Fab fermentations were conducted with the three selected clones, 
HD9, EH8, and EA4 (section 3.2.3). The fermentations were set up on different days. 
 
One colony was selected from the RV308 plate and cultivated in 50 mL of LB (100 µg/ 
mL CARB, 1 % glucose) overnight at 37 °C with 220 rpm shaking. 
 
The cells were transferred to 1,8 L of Terrific Broth (TB) (100 µg/ mL CARB, 0,01 % 
glucose). The 1,8 L cultivation was divided to six 2 L erlemayers, 300 mL of media to 
each of the bottles. The cells were incubated at 37 °C with 220 rpm shaking until their 
growth reached an exponential phase. Growth rate of the bacteria was determined by 
measuring absorbance values with the OD600 method. 
 
IPTG (300 µL, 1 M) was added to each of the 300 mL cultivations. The fermentation 
was performed overnight at 30 °C with approximately 220 rpm shaking. The fermenta-
tion media was centrifuged 20 min at 4 °C with 8 000 rpm. After the centrifugation cell 
pellets were discarded, and combined supernatants were treated with 1 mg of DNAse I 
(Roche Oy) and 0,5 mL of 1 M MgCl2 per 1 L of the supernatant. After the enzyme ad-
dition, the supernatant was incubated 1 h at 37 °C with 140 rpm shaking. The superna-
tant was filtered with vacuum flask equipped with two filter papers (Whatman™, 
GLASS MICROFIBRE FILTERS, GF/C Circles Ø110 mm) and stored at 4 °C.  
3.4 The purification of the produced T3-specific Fabs 
 
3.4.1 Concentration and buffer exchange with Pellicon PLCGC cassette 
 
The supernatant, containing the secreted proteins, from the 2 L fermentation (section 
3.3.5) was refiltered with a vacuum flask as previously described (section 3.3.5).  
 
Filter cassette’s (Pellicon PLCGC 10K 0,5 m2, regenerated cellulose, Merck Millipore 
Ltd.) storage buffer (0,02 % NaN3) was rinsed with 3 L of ultrapure water (Milli-Q, Milli-
pore Corporation). Another 1 L of Milli-Q was recirculated through the cassette for half 
an hour. After the washing the cassette was equilibrated to a new buffer, 10 mM Hepes 
0,5 M NaCl2, by rinsing it with 500 mL and recirculating with 500 mL of the buffer. 
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The supernatant was concentrated by filtration with the Pellicon cassette. Retentate 
was discarded and permeate returned to the concentrated supernatant until the total 
volume of the supernatant was quartered. After the filtration step, the volume of the 
supernatant was increased back to the original by an addition of the buffer. In order to 
exchange the buffer to an adequate extent, the filtration and buffer addition was re-
peated two more times. After the filtration of the last round, the total volume was ad-
justed to 1 L. The concentrate was stored at a temperature of 4 °C. 
 
3.4.2 The immobilized metal affinity chromatography purification 
 
Immobilized metal affinity chromatography (IMAC) purification was applied to the three 
Fab-containing concentrates obtained from the cassette filtrations (section 3.4.1). The 
IMAC purification was executed on different days for each of the concentrates. 
 
The IMAC purification was preceded by charging of Chelating Sepharose® Fast Flow 
(GE Healthcare) with nickel ions. 15 mL of the Sepharose was washed two times with 
15 mL of Milli-Q. 7,5 mL 0,2 M NiCl2 solution was added to the Sepharose. To remove 
excess of the Ni-ions, the Sepharose was washed three times with 30 mL of 0,05 M 
sodium acetate 0,1 M NaCl2 solution (pH 4, pH adjusted with 50 % acetic acid). The 
next washing, 3 x 15 mL, was implemented with charged Sepharose’s storage buffer 
(10 mM Hepes pH 7,4, 1 M NaCl2, 10 % (v/v) glycerol and 1 mM imidazole pH 7,4, 
Sigma-Aldrich Co.). The Sepharose was equilibrated to the same buffer and stored at 4 
°C. 
 
As much as 4 mL of the Ni2+ coupled Sepharose was added to 1 L of the concentrate 
(section 3.4.1) and the mixture was incubated overnight at 4 °C with vertically rotational 
mixing (< 10 rpm). After the incubation, the mixture was left to sediment for 1 h at RT 
with no mixing. The mixture was slowly poured to 50 mL NUNC column (Bio-Rad). 
While the Sepharose was caught in the filter of the column, liquids flowed through and 
were discarded. The column was washed with four washing solutions containing grad-
ually increasing concentrations (1, 5, 10 and 20 mM) of imidazole, 10 mM HEPES pH 
7,4 and 1 M NaCl2. After the washings, twelve elution buffers, with imidazole concen-
trations varying from 50 mM to 500 mM, were applied to release the Fabs, which had 
bound to the charged Sepharose. As well as the washing fractions, all of the elution 
fractions were collected during the purification. The formulas and the volumes of the 
elution and washing fractions are described more detailed in Appendix 2. 
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Protein concentrations of the collected fractions were estimated with Pierce™ BCA 
Protein Assay kit. The assay was conducted with a protocol analogous to the section 
3.1.2. The fractions expressing the highest protein concentrations were selected for 
SDS-PAGE. Fab-specific western blot was applied to estimate the efficiency of the pu-
rification and elution steps from the beginning of the IMAC purification. 
 
Samples were prepared simultaneously for SDS-PAGE and western blot, and Henri 
Arola’s anti-T3 Fab was utilized as a control. Each IMAC fraction was diluted in DDIW 
to obtain the right sample concentrations, 1 µg per well for SDS-PAGE and 200 ng per 
well for Western blot. Final sample volume for each fraction was 20 µl, including 15 µl 
of the sample dilution and 5 µl of 4x Laemmli Sample Buffer (LSB, without β- mercap-
toethanol, VTT). Sample dilutions were mixed to 4 x LSB and heated at 88,5 °C for five 
minutes. Samples and ladders (7 µl of Precision Plus Protein™ Dual Color Standards, 
Bio-Rad) were loaded into the pre-cast wells in 15 % SDS gel provided by Armi Bo-
man. Empty wells were loaded with 15 µl of DDIW supplemented with 5 µl of 4 x LSB. 
Electrophoresis was conducted with Mini-PROTEAN Tetra System (Bio-Rad) and 
PowerPac Basic (Bio-Rad) in 1 x RB with 0,001 % SDS. For the first half an hour the 
current was set to 10 mA per gel, and then increased to 50 mA per gel. 
 
After the electrophoresis the protocols for SDS-PAGE and Western blot separated. In 
Western blot the proteins were transferred to a nitrocellulose paper (Trans-Blot® Tur-
bo™ Mini Nitrocellulose Transfer Packs, Bio-Rad) by plotting (7 min, 2,5 A and 25 V, 
Trans-Blot® Turbo Transfer System, Bio-Rad). Blotting was followed by blocking with 
1,5 % milk powder (Fat-free milk powder 500 g, Valio Oy) in DDIW for 15 min. The ni-
trocellulose paper was washed three times for 5 minutes in TBST (0,05 % Tween 20) 
and incubated for an hour with detection antibody (GoatAnti-Mouse Kappa-AP diluted 
to 1:2000 in 0,05 % TBST, SouthernBiotech). Free detection antibodies were washed 
with the protocol described above. A detection solution, 33 µl of BCIP mixed to 66 µl of 
NBT in 10 mL of AP buffer (100 mM Tris pH 9,5, 100 mM NaCl and 5 mM MgCl2), was 
applied on the paper and after approximately five minutes of incubation, the developed 
colour reaction was terminated by washing the nitrocellulose paper with DDIW. 
 
In SDS-PAGE, three ten-minute washings with DDIW followed the electrophoresis. 
Washed gel was fixated in 20 % isopropanol 10 % acetic acid solution (10 mL, 5 min). 
After fixation the gel was washed with DDIW and coloured in PageBlue solution (Ther-
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mo Scientific Inc.) for one hour at + 50 °C. The excess of the PageBlue was rinsed with 
DDIW and the gel was stored in 10 % glycerol at least overnight before its drying. 
 
The richest Fab fractions with the least impurities were selected according to the SDS-
PAGE and western blot results. By combining the selected fractions, one pool was cre-
ated from each of the Fabs. 
 
3.4.3 The dialysis, concentration and SDS-PAGE for the Fab pools 
 
The buffers of the Fab pools, which were created from the IMAC fractions (section 
3.4.2), were exchanged by a dialysis with Visking Size 3 dialysis tube (Medical Interna-
tional Ltd., molecular weight cut off (MWCO) of 12 – 14 kD) in 2 x 5 L of PBS with 
magnetic stirring.  
 
The protein concentrations of the pools were estimated with Pierce™ BCA Protein As-
say kit with Fab samples (4, 2, 1, 0,5, and 0,25 mg / mL, Helena Henno) as protein 
standards. The pools were concentrated to ~ 2 mg / mL with 10 000 NMWL Amicon® 
Ultra – 15 Centrifugal Filters (Merck Millipore Ltd.) according to the manufacturer’s in-
structions. The Efficiency of the concentration was estimated with Pierce™ BCA Pro-
tein Assay kit (protocol identical to section 3.4.3.). 
 
Overall purity and the protein concentrations of the pools were estimated with SDS-
PAGE (protocol analogous to the section 3.4.2) and anti-T3 control Fab. 
 
3.5 The further characterization of the T3-specific Fabs 
 
3.5.1 The determination of the Fab concentrations of the pools 
 
In order to estimate the affinities of the T3-specific Fabs, the Fab concentrations had to 
be measured as accurate as possible. In the erstwhile conditions, the available time 
was the determinative factor in the consideration of the best quantifying methods. 
 
The Fab concentrations were determined by measuring the protein concentrations from 
three dilutions, 1:5, 1:10 and 1:20, of each pool with two spectrophotometric devices, 
NanoDrop 1000 Spectrophotometer and BioPhotometer (Eppendorf AG). The optical 
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densities of the samples were measured at a wavelength of 280 nm and an average 
was calculated from the results of both devices. 
 
Fab concentration was calculated by proportioning the averaged protein concentration 
by an extinction coefficient. The extinction coefficients, dependent on the amino acid 
sequences of the Fabs’, were obtained from ExPASY Bioinformatics Resource Portal, 
by exploiting their ProtParam tool. 
3.5.2 The determination of the linear ranges of the anti-T3 Fabs  
 
The linear range of an antibody refers to the range of antibody concentrations that can 
be used for accurate measurements in a particular assay. It is a reflection of the quality 
of the standard curve, which should have a defined linear portion indicating the area 
where the antibody is giving predictable responses, dependent upon the concentration 
of the antigen. A successful and reliable characterisation of the affinity of an antibody 
by ELISA requires that the antibody is applied to the assay within its linear range. 
 
For the determination of the linear ranges of Fabs via ELISA, MaxiSorp® NUNC-
IMMUNO C96 96-well plate was coated with 300 ng of T3-HSA per well. T3-HSA was 
diluted to final concentration of 3 µg / mL with 0,1 M sodium bicarbonate buffer (pH 
9,6). The coating was implemented overnight at 4 °C. After the coating, the plate was 
washed three times with 280 µl of PBST (PBS + 0,05 % Tween® 20). 
 
100 µl of each Fab dilution (4, 3, 2, 1, 0,5, and 0 µg of Fab per 1 mL of PBS + 1 % 
DMSO) was pipetted per well. Henri Arola’s anti-T3 and anti-T4 Fabs were applied as 
controls. After a one-hour incubation, unbound Fabs were washed off with PBST (0,05 
% Tween® 20) in the manners described before. 100 µl of detection antibody (1:1000 
dilution of Fab-specific Anti-mouse IgG AP, Sigma-Aldrich Co.) was pipetted to each 
well and the plate was incubated for an hour. Washing, identical to the washes before, 
followed the incubation. 100 µl of pNPP DEA solution (2 mg / mL) was added to each 
well and the A405 values were measured with SPECTROstar Omega spectrometer. 
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3.5.3 The affinity determination 
 
96-well ELISA plate, MaxiSorp® NUNC-IMMUNO C96, was prepared for the assay as 
described in section 3.5.2. 
 
According to the linear ELISA and previous studies (Henri Arola, 2011), the Fabs were 
diluted to concentrations within the linear ranges, T3-specific Fabs, K4HD9 and anti-T3 
control Fab, to 1,5 and 3 µg / mL and multispecific T3-binders, K4EH8 and anti-T4 con-
trol Fab, to 0,25 and 0,5 µg / mL PBS. 
 
The Fabs (350 µL) were preincubated for an hour with 350 µl of each of the T3 dilutions 
(final 0,0001, 0,001, 0,01, 0,1, 1 and 10 µM in 2 % PBS DMSO). Preincubation was 
implemented at RT with 220 rpm shaking. Three parallel samples, á 100 µl, from each 
mixture were transferred to the coated and washed ELISA plate. The mixtures were 
incubated on the plate for one hour at the same conditions as the preincubation. 
 
The detection step was conducted with a protocol identical to the section 3.5.2 
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4 Results 
 
4.1 The transformation efficiency 
 
Transformation efficiency was calculated according to the quantity of the exogenous 
DNA (1 µg), XL1-Blue cells (100 µL) and the number of colonies formed during the 
plate cultivation. Transformation was conducted with four differently ligated Addams 
libraries (LH1, LH2, HL1 and HL2, Henri Arola). After the transformation, the cell cul-
tures were combined to create an antibody library with a higher diversity. The transfor-
mation of the HL1 library is selected as an example. The calculation of the library size 
and transformation efficiency is described below (Table 3.). All of the transformations 
(LH1, LH2, HL1 and HL2) are summarized in Table 4. 
 
Vtot = 100 µL XL1-Blue cells + 3 mL SOC + 7 mL SB = 10,1 mL 
mDNA = 1 µg DNA 
mDNA / Vtot = 0,0990099 µg / mL = 99,0099 ng / mL = 99,0099 pg / µL 
 
Table 3. Library size and transformation efficiency of Addams HL1: 
Dilution V_cells (µL) m_DNA (µg)  Colonies cfu / mL cfu / µg DNA 
2 * 10-6  0,01 9,90E-04 323 3,23E+07 3,26E+05	  
2 * 10-7  0,001 9,90E-05 43 4,30E+07 4,34E+05	  
2 * 10-8  0,0001 9,90E-06 5 5,00E+07 5,05E+05	  
	  	   	  	   	  	   Average: 4,18E+07 4,22E+05	  
 
Table 4. Summary of the transformations. The library sizes and transformation efficiencies 
for Addams LH1, LH2, HL1 and HL2 transformated libraries. 
	  	   LH1	   LH2	   HL1	  	   HL2	  
Library	  size	  (cfu	  /	  mL)	   3,09E+07	   1,81E+07	   4,18E+07	   2,28E+07	  
Transformation	  efficiency	  (cfu	  /	  µg	  DNA)	   3,12E+05	   1,83E+05	   4,22E+05	   2,30E+05	  
Sum	  of	  the	  library	  sizes	  (cfu	  /	  mL)	   1,14E+08	   	  	   	  	   	  	  
 
According to the results, the transformation was successful and efficient. Total library 
size was at the same range with the original Addams library (108 phage particles per 
mL). 
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4.2 The results of the phage ELISA 
 
The phage ELISA was applied to all of phage pools obtained from the biopanning. The 
assay was conducted to detect the phage pools’ specificities against the T3-HSA and 
the HSA, which was applied as a background for the ELISA. The A405 values were 
measured for three phage pool dilutions (1:10, 1:100 and 1:1000) after 10, 20 and 35 
minutes. The results of the last measurements of both the acidic and alkaline eluted 
pools are illustrated in Figure 7. Ratios between the A405 averages of T3-HSA and 
HSA (background) are presented in Figure 8. 
 
 
 
Figure 7. The results of the primary ELISA. The pools obtained with acidic elution (A) and 
the pools obtained with alkaline elution (B).  
  
0,00 
0,50 
1,00 
1,50 
2,00 
2,50 
3,00 
T3
-H
S
A 
H
S
A 
T3
-H
S
A 
H
S
A 
T3
-H
S
A 
H
S
A 
T3
-H
S
A 
H
S
A 
T3
-H
S
A 
H
S
A 
R I R II R III R IV R V 
A
bs
or
ba
nc
e 
(A
40
5)
 
Sample / Backround / Selection round 
Phage ELISA: Acidic elution, 35 min  
1:10 
1:100 
1:1000 
Phage 
dilution 
A) 
0,00 
0,50 
1,00 
1,50 
2,00 
2,50 
3,00 
T3
-H
S
A 
H
S
A 
T3
-H
S
A 
H
S
A 
T3
-H
S
A 
H
S
A 
T3
-H
S
A 
H
S
A 
T3
-H
S
A 
H
S
A 
R I R II R III R IV R V 
A
bs
or
ba
nc
e 
(A
40
5)
 
Sample / Backround / Selection round 
Phage ELISA: Alkaline elution, 38 min 
1:10 
1:100 
1:1000 
Phage 
dilutio
n 
B) 
34 
 
 
Figure 8. The results of the primary ELISA applied to the phage pools eluted with the acid-
ic elution mixture presented as ratio between the averages (A405) of T3-HSA and HSA 
(background). Red line represents the zero point, where the absorbance values are not 
differing between T3-HSA and HSA. Upper in the Figure are the pools obtained with 
acidic elution (A) and lower are the pools obtained with alkaline elution (B). 
 
The ELISA clearly shows the enrichment of T3-specific Fabs, between the rounds II – 
V. According to the results, rounds from II to V from both elutions expressed significant 
specificity against T3-HSA, when compared to the specificity against HSA. The first 
rounds of both elutions gave ‘negative’, although expected, results and thus were left 
out from the further screenings. 
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4.3 The results of the primary screenings against T3-HSA, T4-HSA and HSA 
 
96 XL1-Blue clones from each of the output plate cultivations of the T3-specific pools 
(rounds II – V) were collected and screened against T3-HSA, T4-HSA and HSA with the 
primary ELISA. As an example of the results, A405 absorbance values of 16 clones of 
the fourth alkaline eluted round are presented in Figure 9. A405 values of the best 20 
clones selected according to this primary screening assay are gathered to Figure 9. 
The results suggest, that the clone K4HD9 (HD9, blue-framed star in Figure 9) seems 
to be the most specific against T3-HSA and that the clone K4EH8 (EH8, red-framed 
star in Figure 9) binds T4-HSA with the highest affinity. 
 
 
Figure 9. Primary screening results: A) is an example of fourth alkaline eluted round (only 
clones 45 – 60). The clone with highest affinity against T3-HSA (HD9) is marked with 
blue-framed star. The 20 clones, selected according to the screenings, are presented in 
B). Multispecific high-affinity clone (EH8) is marked with the red-framed star. 
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Summary of the 33 positive and 4 T3-specific clones discovered with the screening is 
presented in Figure 10. The *clones whose A405 response against T3-HSA was at 
least twofold compared to the response against HSA were categorized as positive. All 
**positive clones whose T3-HSA / HSA –ratio was at least twofold to its T4-HSA / HSA –
ratio, were considered as T3-specific. 
 
 
Figure 10. Summary of the 33 T3-positive and 4 T3-specific clones of each selection round 
from both of the elution methods, the acidic (Ac) and alkaline (Al). 
 
4.4 The T4 and HSA cross-reactivities of the selected clones 
 
In order to reduce the number of the selected clones, the phagemid DNA of the 20 
clones was sequenced and their cross-reactivities were tested against T3, T4, and HSA. 
Fabs’ specificities against T3 and T4 were tested by competitive screening with only one 
hapten dilution (final 20 µM) for each hapten. The ELISA plates were coated with 100 
ng of T3-HSA per well. The results of the competitive cross-reactivity ELISAs are pre-
sented as A405 values below in Figure 11. In the figures the height of the bar is indicat-
ing the clone’s affinity against the corresponding hapten applied to the pre incubation 
(T3 and T4). The lower the bar, the bigger the affinity is against the hapten. In Figure 
11, the most specific clone, K4HD9, is marked with blue-framed star, multispecific 
K4EH8, expressing relatively high affinity against all of the haptens, with red-framed 
star and K4EA4, an interesting clone expressing specificity against T3 with green-
framed star. 
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Figure 11. A405 Results of the cross-reactivity ELISA: A) the clones 1 – 10, B) the clones 
11 – 20. 
 
K4EA4 seems to behave similarly to the K4HD9, but with overall lower responses. 
When compared to the results of the clones 1 – 10, the clones 11 – 20 do not appear to 
have significant specificities against any of the haptens. K5EC9 and K2EB8 are pre-
senting minor specificity against T3. Despite that K2EB8’s relative specificity against T3 
is around 2-fold to the specificity against T4, the antibody suffers from the low total re-
sponse (A405 < 0,5) and therefore was not chosen for further studies. 
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4.5 The DNA analysis 
 
Phylogenetic trees were created based on the analysis conducted to the sequencing 
data of the heavy and light chains of the Fabs. As an example, the phylogenetic tree 
presented in Figure 12, is created from the data obtained from the light chain sequenc-
ing. The sequencing of the heavy chains encountered difficulties and failed, at least 
partly, for twelve of the twenty clones, including K4HD9. 
 
 
Figure 12. Phylogenetic tree created based on the light chain sequencing data. Picture illus-
trates relations between the light chain sequences of the clones.  
 
In comparison, T3-specific Fab clone, previously obtained from the same library by Aro-
la, was included to the analysis of the light chains. The sequencing data revealed that 
ten of the twenty clones were identical by their light chain sequences. The phylogenetic 
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tree illustrates similarities in the genotypes, and suggest that the most promising and 
interesting clones, the T3-specific K4HD9 (blue-framed star in picture) and the highest 
affinity clone K4EH8 (red-framed star in picture) were closely related to the anti-T3 con-
trol Fab (light brown-framed star in picture). According to the sequencing data and the 
ELISAs, the six most interesting clones were selected to further analysing.  
 
4.6 The competitiveness of the selected anti-T3 clones 
 
A more detailed competitive ELISA was implemented for the clones selected with the 
cross-reactivity ELISA. Competiveness was measured against free T3 and T4 with three 
concentrations (10 µM, 2 µM and 0,2 µM). A405 results of the assay are presented in 
Figure 13. 
 
 
Figure 13. The results of the competitive ELISA. Competiveness was determined against T3 
and T4 with three different concentrations (20, 2 and 0,2 µM). T3-specific K4HD9 is 
marked with the blue-framed star and multispecific K4EH8 with the red-framed star. 
 
According to the ELISA, K4HD9 and K4EA4 are the most T3-specific clones. The re-
sults also confirm the previous conclusions about the multispecificity of the K4EH8. 
Based on the results, K4HD9, K4EH8 and K4EA4 were selected for the small-scale 
production in E.coli and characterization phase. These clones are later referred as 
HD9, EH8 and EA4.   
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4.7 The IMAC purification 
 
After the small-scale production in E.coli, the Fabs were purified from the buffer solu-
tion by IMAC. The protein concentrations of the IMAC fractions were first estimated 
with Pierce™ BCA Protein Assay kit and according to the results of the BCA, the most 
promising fractions with highest protein concentrations were selected for the SDS-
PAGE. An example of the SDS-PAGE results is illustrated in Picture 1. 
 
 
Picture 1. Example of SDS-PAGE applied to IMAC fractions: The IMAC fractions of HD9. 
Fabs, separated by their molecular size, are located between the 37 and 50 kD markers 
(the first column). Legends of the wells are displayed on the right side. The gel was bent 
between columns 8 and 10; therefore, Elution 8 does not contain lower molecular weight 
antibodies than the others.  
 
Since the total protein concentration is approximately the same in each well, it can be 
observed from the picture, that the elution fractions from 5 to 8 have the highest Fab 
concentrations with the least impurities. Western blots were applied to ensure the suc-
cess of the purifications (data not shown). Fab pools were created by combining the 
most pure IMAC fractions of each clone, as an example, fractions from 5 to 8 for HD9 
(Picture 1). 
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4.8 Purity of the Fab pools 
 
After the dialysis and concentration of the Fab pools, an SDS-PAGE with a protein load 
of 1 µg per well was implemented to visualize and compare the purity and protein con-
centration of the created Fab pools. The SDS-PAGE gel is presented in Picture 2.  
 
 
Picture 2. SDS-PAGE of the Fab pools. SDS-PAGE gel was photographed with the light ta-
ble of Molecular Imager Gel Doc™ XR+ (Bio-Rad Laboratories Inc.). SDS-PAGE veri-
fied the successful purification of the produced Fabs.  
 
The blue smear on the third lane (Picture 2) of the gel indicates that the pool of HD9 
probably contained some impurities with relatively large molecular size. The small 
bands, below the actual Fabs, are separate heavy and light chains. Overall, the band of 
the interest, the Fab-fragment, is clearly the major band, and the purity level was suffi-
cient for the further characterisation steps (ELISAs). 
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4.9 The linear ranges of the anti-T3 Fabs 
 
Competitive ELISA with six Fab dilutions (4, 3, 2, 1, 0,5, and 0 µg of Fab per 1 mL of 
PBS + 1 % DMSO) was conducted to determine the linear ranges of the Fabs. The 
ELISA plates were coated with 300 ng of T3-HSA per well. Henri Arola’s clones with 
similar functional profiles, T3-specific (T3-18 in Figure 14) and multispecific (not shown) 
Fabs were applied as controls for HD9, EA4 and EH8. As an example, a point-to-point 
fitting of the A405 results of HD9’s ELISA is presented in Figure 14. 
 
 
Figure 14. Determination of the linear range: HD9. Henri Arola’s anti-T3 (T3-18 in picture) as 
a control. 
 
The determination did not give an unambiguous answer about the linear range of HD9 
and could have been more accurate if the number of the Fab dilutions would have been 
increased. Also, the impurities in the HD9’s Fab pool might have affected to the results.  
 
According to the results of the ELISAs, the linear ranges, the Fabs’ concentration rang-
es where the absorbance is linearly increasing with respect to the quantity of the sub-
strate, were suggested to be between 1 – 2,5 µg / mL for HD9 and 0,2 – 1,5 µg / mL for 
EH8. EA4’s responses in ELISA were too weak for the determination, and therefore 
this clone was not further studied. However, all of the ELISA results are depending on 
the assay conditions, such as buffer composition and pH; therefore, the same assay 
conditions were applied for the competitive ELISA.   
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4.10 The determined affinities of HD9 and EH8 against the T3  
 
Linear ranges of the Fabs were estimated with the primary ELISA. Fab concentrations 
for the competitive ELISA were selected from within the Fabs’ linear ranges. Linear 
range determination failed for the EA4 and thus it was rejected from the assay. Com-
petiveness of HD9 and EH8 against T3 is illustrated in the bar diagrams (Figure 15).  
 
 
Figure 15. Competitive ELISA: A) antibody HD9 1,5 µg / mL, T3 0,001, 0,01, 0,1, 1 and 10 
µM, B) antibody EH8 0,25 µg / mL, T3 0,001, 0,01, 0,1, 1 and 10 µM. 
 
The results suggest that with both of the clones the free T3 starts to compete at submi-
cromolar concentrations. However, the amount of applied EH8 was only one-sixth of 
the HD9’s; and hence the competition can be stated to be remarkably stronger with 
EH8 than with HD9. Another aspect seconding the estimate is, that with HD9 a clear 
inhibition can be observed at 1 µM and with EH8 at 0,1 µM T3 concentration. The assay 
was not optimized to the required level to make more accurate determinations on Fabs’ 
affinities against the T3. Although, it clearly indicates that the Fabs (HD9 and EH8) are 
T3-binders. 
0 
0,05 
0,1 
0,15 
0,2 
0,25 
0,3 
0,35 
0,001 0,01 0,1 1 10 
A
bs
or
ba
nc
e 
(A
40
5)
 
Concentration of free T3 (µM) 
Competive ELISA: HD9 Antibody, Assay time 22 min 
HD9 1,5 µg / mL 
A) 
0 
0,1 
0,2 
0,3 
0,4 
0,001 0,01 0,1 1 10 
A
bs
or
ba
nc
e 
(A
40
5)
 
Concentration of free T3 (µM) 
Competive ELISA: EH8 Antibody, Assay time 35 min 
EH8 0,25 ug / mL 
B) 
44 
 
5 Discussions 
 
5.1 The library transformation 
 
Recombinant DNA can be introduced into competent E.coli cells either by chemical 
transformation or electroporation. The chemical method, also known as heat shock 
method, is cost-effective and reliable, but electroporation can be over ten times more 
efficient. As described in section 2.3.1, the size and the quality of the library are one of 
the main factors affecting to the outcome when developing antibodies with in vitro 
techniques [20; 15]1. As such, the electroporation was selected to maximize the library 
size.  
 
Transformation was conducted with four differently ligated Addams libraries (LH1, LH2, 
HL1 and HL2, Henri Arola). After the transformation, the cell cultures were combined to 
create an antibody library with higher diversity. The total library size (108 cfu / mL) was 
at the same range with the previous transformation of the same library (Henri Arola, 
2011). As the transformation succeeded, it provided a good basis for the work. 
5.2 The biopanning 
 
A semi-automated selection method was applied to enrich the T3-specific antibody 
clones. The outcome of the positive clones depends mostly on the library size, antigen, 
selection conditions and the number of selection rounds [15]. The library size was cal-
culated to be sufficient and the antigen, AP conjugated with T3, was provided and vali-
dated by Antti Tullila. The validation and estimation of the conjugation degree was es-
timated mass spectrometrically with MALDI. T3-AP conjugates were biotinylated and 
attached to magnetic streptavidin beads, which were used to enrich the positive clones. 
To increase the efficiency of the panning, it was conducted on semi-automated plat-
form with two elution methods in parallel (alkaline and acidic). Five panning rounds with 
gradually hardened panning conditions were applied to enrich the positive clones. 
 
Since the elution method affects significantly to the antibody outcome of the panning 
and the efficiency of elution methods tend to vary case by case [15], the elutions were 
designed carefully. Multiple efficient elution techniques have been introduced and suc-
cessfully applied to the development of recombinant antibodies (section 2.4), but each 
employed elution method multiplies the amount of work. Thus, it was decided here to 
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do the biopanning with two different elution methods in parallel. The acidic and the al-
kaline elutions were selected mainly based on the positive results gained from the pre-
vious panning of the same library (Henri Arola, 2011).  
 
As assumed, the elution methods affected significantly to the enrichment of clones.  
The antibody clones obtained by acidic elution were not obtained by alkaline elution 
and vice versa. Both methods yielded several positive clones and the outcome of the 
whole panning was 33 positive clones. The alkaline elution yielded 22 out of the 33 
positives and, according to the characterisations (ELISAs), the clone with the highest 
affinity against the T3 (EH8), but the acidic elution provided the most T3-specific clone. 
Respectively, discarding either of the elution methods would have had remarkable in-
fluence to the outcome of the work. 
 
The selection pressure was controlled during the biopanning by adjusting the panning 
conditions (section 3.1.4). The panning conditions were hardened for each of the five 
rounds, to gradually increase the selection pressure against the clones with the highest 
affinity. Besides finding the highest affinity clones, it is desirable to maintain the diversi-
ty of clones high throughout the panning; therefore, it is not ideal to forcefully harden 
the reaction conditions immediately, but rather to use multiple panning rounds. Here, 
the enriching itself did not take into account all properties of the antibodies (e.g. cross-
reactivity or specificity against the free hapten) and thus favoured clones with even 
undesired features. According to the primary screenings of the study, the most en-
riched clones from the last panning round were neither the most specific against T3 nor 
the ones with the highest affinities. All the most interesting clones were from the fourth 
panning round. 
 
With diverse range of clones it is possible to make further analyses to the interesting 
individuals to compare their differences. For example, by mirroring the differences in 
functional properties to the differences in amino acid sequences, it is possible to obtain 
valuable information about the amino acid sequences affecting to the antibody’s prop-
erties, such as affinity and specificity. 
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5.3 The primary screening with SAMI 
 
ELISA assays were applied for the primary screening of the selected panning rounds 
(rounds II – V). The enriched Fabs were screened in ELISAs based on their specificity 
against T3. The specificity (cross-reactivity) was estimated by testing the reactivity 
against the T3 and by comparing the results to the reactivity against T3’s carrier mole-
cule HSA and T3’s metabolic precursor T4. Reactivity against T4 was tested based on 
the previous studies wherein several antibodies reacting with T3 also interacted with T4 
(Tarja Nevanen, personal communication, 2014). T4’s structure differs from T3’s only by 
one iodine atom (section 2.1.1), which may increase the possibility of cross-reactivity. 
Reactivity against the carrier molecule was tested to ensure that the antibodies were 
recognizing only the hapten and not the carrier.  
 
The screening was conducted with the robotic workstation (SAMI), which enabled a 
comprehensive approach. A total of 768 clones, were screened on 24 96-well plates. 
Although employing a robot to do the laborious part of the work saves time, it also in-
creases the amounts of reagents used. Particularly, in the development of novel anti-
bodies the antigen can often be expensive or difficult to arrange in big quantities and 
thus may delimit or make it more unattractive to use automated systems, such as SAMI 
(Tarja Nevanen, personal communication, 2014).  
 
The primary screening with the robot provided a rough estimation about the cross-
reactivity of the clones against T4-HSA and of their affinity against HSA in comparison 
with T3-HSA. Twenty of the most promising clones were selected for the further charac-
terization according to the results. The effect of varying production levels was mini-
mized during the evaluation process by emphasizing the intensity ratios between anti-
gens (T4-HSA / T3-HSA and T3-HSA / HSA). However, if the production level or stability 
of an antibody is low in the assay conditions, the antibody may not be able to give clear 
positive results even if it has high affinity against the antigen.  
 
According to this assay, the T3-positive (T3-HSA had at least twofold increase in inten-
sity when compared to HSA) clones distributed quite unevenly between the two elution 
methods. Alkaline elution yielded twice as much of positives (22 clones) as the acidic 
did (11 clones). The acidic elution has been more widely applied to elutions (Tarja 
Nevanen, personal communication, 2014) than the alkaline, but in this case the alkaline 
yielded bigger number of positive clones. Also, other elution methods such as using an 
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excess of free antigen in elution [36] could have been worth of trying. For example, the 
use of free antigen in excess would not require additional modification for the conjugate 
and could provide a different outcome in contrast to the methods such as acidic and 
alkaline elutions that apply such harsh reaction conditions before the neutralisation (in 
this work pH 2,2 and pH 11,75). 
 
5.4 The characterisation of the anti-T3 clones 
 
Properties of the selected clones were estimated with ELISA assays. Applied assays 
included both linear and competitive ELISAs. Although ELISAs are convenient for rank-
ing the clones by their affinities and cross-reactivity, they do not provide sufficient accu-
racy and reliability for kinetic and affinity analyses (Tarja Nevanen, personal communi-
cation, 2014). For such purposes, more precise and reliable immunoassays, such as 
surface plasmon resonance (SPR) methods (e.g. BiacoreTM) or so-called kinetic exclu-
sion assay (KinExA), are usually required [37 – 39]. 
 
Since the results of ELISAs’ are depending on the assay conditions, they might not be 
valid in other conditions; therefore, they may not be generalized. In addition, our assay 
was not optimized to the required level to make highly accurate determinations on 
Fabs’ affinities against the T3. However, this does not mean that the applied assays 
would not have provided good estimations about the properties of the selected clones. 
Due to the reference samples, which were previously selected and characterized Fab 
clones of the same library, the obtained data concerning the Fabs is especially useful 
and comparable to the results of the previous studies carried out by Henri Arola in 
2011. 
 
According to the results of the competitive ELISA, the selected Fab clones (HD9 and 
EH8) are clearly T3-binders. With both of the competitive ELISA tested clones the free 
T3 started to compete at submicromolar concentrations. According to the ELISAs, the 
behaviour, competitiveness of T3 and the cross-reactivities against T4, of the Fabs was 
remarkably similar to the reference clones provided by Arola (data not shown).  
 
HD9 seemed to be much more specific against the T3 when compared to the multi-
specific EH8 that appeared to recognize even more efficiently the T4 molecule (section 
4.6). Although being more specific, HD9 expressed lower affinity against the T3 than 
EH8 (sections 4.6 and 4.10). The selected Fabs were purified before the assays by 
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IMAC-purification and dialysis, but the minor impurities in the Fab pools (visible in SDS-
PAGE, section 4.8) may have had a slight effect to the obtained results.  
 
By recognizing and characterizing different behaviour profiles, it is possible to efficiently 
compare and study the amino acid sequences between clones. This increases the 
knowledge concerning particular structures and their effects to the functionality and 
binding abilities of the antibodies. This type of knowledge could be utilized, for exam-
ple, to the designing of recombinant antibodies expressing higher specificity and affinity 
against the T3. 
 
5.5 The comparison of the DNA sequences 
 
By comparing the amino acid sequences and the functional properties (e.g. affinity and 
specificity) of the clones with the Fabs sequenced and characterized during the previ-
ous panning of the same library (Henri Arola, 2011), it is possible to connect the differ-
ences in the amino acid sequences to the properties of the antibodies. 
 
Analysis of the sequencing data included formation of phylogenetic threes. Heavy and 
light chain sequences of Arola’s T3-specific Fab were included to the analyses. The 
sequence analysis revealed the interesting fact that both, the clone with the highest 
affinity against the T3 (EH8) and the most T3-specific clone (HD9) were genetically 
closely related to Arola’s anti-T3 Fab. The difference between HD9’s and the anti-T3 
Fab’s light chain amino acid sequences was approximately 6,1 % and between 
K4EH8’s and the anti-T3 Fab’s 7,5 %. Unfortunately, some difficulties occurred in the 
sequencing of HD9’s heavy chain and thus a reliable comparison between it and the 
anti-T3 Fab is not yet possible. Another comparison between the similarly acting multi-
specific clones showed, that the total difference between Arola’s anti-T4 Fab and EH8, 
was only 3,4 %. 
 
The total difference in the amino acid sequences of EH8 and the anti-T3 Fab was rela-
tively small (11,2 %) when compared to the differences of their functional properties. 
While EH8 is a multispecific T3-binder with the highest affinity from the clones obtained, 
the anti-T3 is the most specific of Arola’s clones. When examined closer, it can be 
clearly seen that the differences in the sequences are focused on particular areas of 
the sequences. For example, in the heavy chains, more than half (65,2 %) of the 
changes are located in two of the CDRs (CDR2 and CDR3), areas that together consist 
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of 32 (17 and 15) amino acids (Kabat definition) and affect strongly to the binding abili-
ties of the antibody [15]. The difference between the equivalent areas of EH8’s and the 
anti-T4 Fab’s sequences was 0 %; the heavy chains of the multispecific clones were 
identical regarding to the sequences of the CDRs. Light chains differed by 6,6 %, which 
is not much smaller than the difference between EH8 and the nati-T3. Only one third of 
these changes were on CDRs, which might indicate that the heavy chain might be 
more dominant in the directing of the T3-specificy. 
 
This type of information can be collected from multiple clones, combined, and then uti-
lized to determine the amino acids and antibody structures that are directing the speci-
ficity exclusively towards the T3. By determining the roles of certain amino acids, it can 
be possible to modify antibodies towards the desired direction, for example, to increase 
the specificity of a multispecific high affinity antibody, such as EH8. 
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6 Conclusions 
 
The study succeeded in the development and characterisation of novel T3-binding re-
combinant antibodies. One T3-specific (HD9) and one multispecific fab clone (EH8), 
recognizing both the T3 and T4, were selected, produced and characterized from the 
previously constructed and validated recombinant antibody (Fab) library provided by 
Henri Arola.  
 
The clones were panned from the phage-displayed library by semi-automated biopan-
ning. A robotic workstation was employed to the primary screenings. The final selection 
of the clones and the further characterisation was based on DNA sequencing and 
competitive and linear ELISAs. According to the results of the competitive ELISAs, the 
selected Fab clones (HD9 and EH8) are clearly T3-binders. With both of the clones, the 
free T3 started to compete at submicromolar concentrations. The behaviour, competi-
tiveness of free T3 and cross-reactivity of the Fabs were remarkably similar to the 
clones obtained from the previous study conducted with the same library (Henri Arola, 
2011).  
 
The amino acid sequence comparisons between EH8 and Arola’s multispecific anti-T4 
Fab and T3-specific Fab, revealed interesting differences in the sequences focusing 
especially on the two CDRs (CDR2 and CDR3) of the heavy chains. It is very likely that 
in the future, this type of information could be applied, for example, to the designing 
and modification of recombinant antibodies towards higher specificity and affinity 
against the T3.  
 
To increase the value of the information obtained from the study, kinetics and affinity of 
the selected clones (HD9 and EH8) could be analysed more deeply, for example, with 
BiacoreTM. For a more complete analysis of the obtained T3-specific clone, HD9, suc-
cessful sequencing of the heavy chain would be mandatory. Amino acid sequence 
comparison between high-affinity multispecific clones, such as EH8 and the anti-T4 
Fab, and HD9 could probably provide valuable information about the amino acid se-
quences responsible for the antigen binding abilities. 
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Appendices 
 
Appendix 1: Reagent list 
 
Cuts All (CA) buffer: 
 200 mM Tris-HCl, pH 7,5 
 70 mM MgCl2 
 1000 mM KCl 
 20 mM 2-mercaptoethanol 
 Store at +4 °C 
 
4 x LSB - β-mercaptoethanol 
 23,4 mL DDIW 
 5 mL 1M Tris, pH 6,8 
 11,6 mL 87 % Glycerol 
 2 g SDS (or 10 mL 20 % SDS) 
 10 mg Bromphenol blue 
 Store at - 20 °C 
 
Luria Broth (LB): 
 5 g / 1 000 mL Yeast Extract 
 10 g / 1 000 mL Tryptone 
 10 g / 1 000 mL NaCl 
 15 g / 1 000 mL Agar (granulated) 
 For Luria Broth ampicillin plates: 100 mg / mL AMP 
 
10 x PBS: 
 0,12 M Na2HPO4  2 H2O, 42,7 g 
 0,03 M NaH2PO4  H2O, 8,3 g 
 1,5 M NaCl, 175,3 g 
 DDIW 2 000 mL 
 (Diluted to 1 x PBS, pH 7,30) 
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10 x Reducing Buffer (RB): 
 250 mM Tris, 151,3 g 
 1,92 M Glycine, 721 g 
 DDIW, 5 000 mL 
 Do not require pH adjustment, Store at RT or + 4 °C 
 
Super Optimal Broth (SOB): 
 Tryptone, 20 g 
 Yeast extract, 5 g 
 NaCl, 0,58 g 
 KCl, 0,18 g 
 DDIW 1 000 mL 
 Add 1M MgCl2 and 1 M MgSO4, 1 mL / 100 mL before use 
 
Super Optimal broth with Catabolite repression (SOC): 
 SOB + 20 % Glucose (49:1 = 0,4 % final) 
 
Super Broth (SB): 
 30 g / 1 000 mL Tryptone 
 20 g / 1 000 mL Yeast Extract 
 10 g / 1 000 mL 3-(N-Morpholino)propanesulfonicacid  
 (MOPS, Sigma-Aldrich Co.) 
 pH adjusted to 7,0 with 5 M NaOH 
 
10 x TBS (and 1 x TBST): 
 500 mL 1M Tris-HCl, pH 8,0 
 438,3 g NaCl 
 DDIW to 5 000 mL final volume 
 Diluted to 1 x TBS when used 
 For 1 x TBST: add 0,5 mL Tween® 20 / 1 000 mL 1 x TBS before use
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Appendix 2: Solutions and fractions of the IMAC purification 
 
Table 1. Formulas of the washing and the elution solutions. The stock solutions were 2 M 
imidazole, 1 M HEPES (pH 7,4) and 1 M NaCl2.  
 
 
 
Table 2. Volumes and imidazole concentrations of the washing and the elution fractions of 
the IMAC purification. 
  
Name	  of	  the	  buffer V_tot	  (mL) V_Imidazole	  (mL) V_HEPES	  (mL) V_NaCl2	  (mL) V_MilliQ	  (mL)
Washing_buffer	  1 1 mM 300 0,15 3 150 146,85
Washing_buffer	  2 5 mM 200 0,5 2 100 97,5
Washing_buffer	  3 10 mM 200 1 2 100 97
Washing_buffer	  4 20 mM 200 2 2 100 96
Elution_buffer	  1 50 mM 200 5 2 100 93
Elution_buffer	  2 75 mM 150 5,625 1,5 75 67,875
Elution_buffer	  3 100 mM 150 7,5 1,5 75 66
Elution_buffer	  4 200 mM 200 20 2 100 78
Elution_buffer	  5 500 mM 200 50 2 100 48
C_imidazole
Washing	  # C_Imidazole V_tot	  (mL)
1. 1	  mM 60
2. 5	  mM 25
3. 10	  mM 25
4. 20	  mM 25
Elution	  # C_Imidazole V_tot	  (mL)
1. 50	  mM 10
2. 50	  mM 10
3. 50	  mM 10
4. 75	  mM 10
5. 75	  mM 10
6. 75	  mM 10
7. 100	  mM 10
8. 100	  mM 10
9. 200	  mM 10
10. 200	  mM 10
11. 500	  mM 10
12. 500	  mM 10
